U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Secondary Central Nervous System Lymphoma

MedGen UID:
453610
•Concept ID:
C2981383
•
Neoplastic Process

Definition

A non-Hodgkin or Hodgkin lymphoma that has spread to the central nervous system following the initial presentation in another nodal or extranodal site. [from NCI]

Professional guidelines

PubMed

Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich J
Neuro Oncol 2023 Dec 8;25(12):2239-2249. doi: 10.1093/neuonc/noad118. PMID: 37402650Free PMC Article
Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
Orellana-Noia V, Abousaud A
Curr Treat Options Oncol 2022 Oct;23(10):1443-1456. Epub 2022 Sep 21 doi: 10.1007/s11864-022-01017-4. PMID: 36127571

Recent clinical studies

Etiology

Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich J
Neuro Oncol 2023 Dec 8;25(12):2239-2249. doi: 10.1093/neuonc/noad118. PMID: 37402650Free PMC Article
Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N, Masood A, Dhaliwal A, Khurana S, Davis J, Hashmi H, Husnain M
Clin Lymphoma Myeloma Leuk 2023 Jan;23(1):15-21. Epub 2022 Oct 7 doi: 10.1016/j.clml.2022.09.008. PMID: 36328891
Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, Vitolo U
Expert Rev Hematol 2019 Sep;12(9):787-796. Epub 2019 Aug 8 doi: 10.1080/17474086.2019.1643232. PMID: 31305170
Secondary central nervous system lymphoma.
Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y
Int J Hematol 2006 Aug;84(2):128-35. doi: 10.1532/IJH97.06091. PMID: 16926134

Diagnosis

Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
Orellana-Noia V, Abousaud A
Curr Treat Options Oncol 2022 Oct;23(10):1443-1456. Epub 2022 Sep 21 doi: 10.1007/s11864-022-01017-4. PMID: 36127571
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
Magnes T, Wagner S, Thorner AR, Neureiter D, Klieser E, Rinnerthaler G, Weiss L, Huemer F, Zaborsky N, Steiner M, Weis S, Greil R, Egle A, Melchardt T
ESMO Open 2021 Feb;6(1):100012. Epub 2021 Jan 4 doi: 10.1016/j.esmoop.2020.100012. PMID: 33399078Free PMC Article
Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, Vitolo U
Expert Rev Hematol 2019 Sep;12(9):787-796. Epub 2019 Aug 8 doi: 10.1080/17474086.2019.1643232. PMID: 31305170
Secondary central nervous system lymphoma.
Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y
Int J Hematol 2006 Aug;84(2):128-35. doi: 10.1532/IJH97.06091. PMID: 16926134

Therapy

Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N, Masood A, Dhaliwal A, Khurana S, Davis J, Hashmi H, Husnain M
Clin Lymphoma Myeloma Leuk 2023 Jan;23(1):15-21. Epub 2022 Oct 7 doi: 10.1016/j.clml.2022.09.008. PMID: 36328891
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735Free PMC Article
Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
Orellana-Noia V, Abousaud A
Curr Treat Options Oncol 2022 Oct;23(10):1443-1456. Epub 2022 Sep 21 doi: 10.1007/s11864-022-01017-4. PMID: 36127571
Central Nervous System Lymphoma.
Chukwueke UN, Nayak L
Hematol Oncol Clin North Am 2019 Aug;33(4):597-611. Epub 2019 May 10 doi: 10.1016/j.hoc.2019.03.008. PMID: 31229157

Prognosis

Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N, Masood A, Dhaliwal A, Khurana S, Davis J, Hashmi H, Husnain M
Clin Lymphoma Myeloma Leuk 2023 Jan;23(1):15-21. Epub 2022 Oct 7 doi: 10.1016/j.clml.2022.09.008. PMID: 36328891
Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
Orellana-Noia V, Abousaud A
Curr Treat Options Oncol 2022 Oct;23(10):1443-1456. Epub 2022 Sep 21 doi: 10.1007/s11864-022-01017-4. PMID: 36127571
Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, Vitolo U
Expert Rev Hematol 2019 Sep;12(9):787-796. Epub 2019 Aug 8 doi: 10.1080/17474086.2019.1643232. PMID: 31305170
Central Nervous System Lymphoma.
Chukwueke UN, Nayak L
Hematol Oncol Clin North Am 2019 Aug;33(4):597-611. Epub 2019 May 10 doi: 10.1016/j.hoc.2019.03.008. PMID: 31229157
Secondary central nervous system lymphoma.
Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y
Int J Hematol 2006 Aug;84(2):128-35. doi: 10.1532/IJH97.06091. PMID: 16926134

Clinical prediction guides

Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich J
Neuro Oncol 2023 Dec 8;25(12):2239-2249. doi: 10.1093/neuonc/noad118. PMID: 37402650Free PMC Article
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735Free PMC Article
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
Zhang H, Yan Z, Wang Y, Qi Y, Hu Y, Li P, Cao J, Zhang M, Xiao X, Shi M, Xia J, Ma S, Qiao J, Li H, Pan B, Qi K, Cheng H, Sun H, Zhu F, Sang W, Li D, Li Z, Zheng J, Zhao M, Liang A, Huang H, Xu K
Front Immunol 2022;13:965224. Epub 2022 Aug 19 doi: 10.3389/fimmu.2022.965224. PMID: 36059496Free PMC Article
Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, Vitolo U
Expert Rev Hematol 2019 Sep;12(9):787-796. Epub 2019 Aug 8 doi: 10.1080/17474086.2019.1643232. PMID: 31305170
Secondary central nervous system lymphoma.
Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y
Int J Hematol 2006 Aug;84(2):128-35. doi: 10.1532/IJH97.06091. PMID: 16926134

Recent systematic reviews

Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N, Masood A, Dhaliwal A, Khurana S, Davis J, Hashmi H, Husnain M
Clin Lymphoma Myeloma Leuk 2023 Jan;23(1):15-21. Epub 2022 Oct 7 doi: 10.1016/j.clml.2022.09.008. PMID: 36328891
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...